[Market Focus] Samsung Biologics Rises for Six Consecutive Days on Earnings Expectations

Samsung Biologics has continued its upward trend for six consecutive days.

As of 9:18 a.m. on October 15, 2025, Samsung Biologics was trading at 1,097,000 won on the Korea Exchange, up 70,000 won (6.82%) from the previous day.

Expectations for strong earnings appear to be driving the stock price higher. On this day, Kiwoom Securities projected that Samsung Biologics would post consolidated third-quarter sales of 1.6247 trillion won, up 37% year-on-year, and operating profit of 646.2 billion won, up 91% from a year earlier. Heo Hyemin, a researcher at Kiwoom Securities, stated, "We expect sales and operating profit to exceed the market consensus (the average forecast by securities firms) of 1.5506 trillion won and 505.2 billion won by 5% and 28%, respectively." She explained that favorable exchange rates, milestone payments from Samsung Bioepis, and the leverage effect of full-capacity operation at Plant 4 are expected to contribute to strong results.